Docetaxel vs Docetaxel and Irinotecan for Lung Cancer
Author Information
Author(s): Wachters F M, Groen H J M, Biesma B, Schramel F M N H, Postmus P E, Stigt J A, Smit E F
Primary Institution: University Hospital Groningen
Hypothesis
Does the addition of irinotecan to docetaxel improve response rates in patients with advanced non-small-cell lung cancer?
Conclusion
Adding irinotecan to docetaxel does not improve response rates and increases gastrointestinal toxicity in patients with advanced lung cancer.
Supporting Evidence
- Overall response rate was 16% for docetaxel alone and 10% for the combination treatment.
- Diarrhea was more frequently observed in the combination treatment group.
- Median overall survival was 32 weeks for docetaxel alone and 27 weeks for the combination treatment.
Takeaway
This study looked at two treatments for lung cancer and found that one treatment didn't work better than the other, but it caused more stomach problems.
Methodology
Patients were randomized to receive either docetaxel alone or docetaxel combined with irinotecan, and their responses were evaluated based on tumor response rates and toxicity.
Limitations
The study was not powered to detect differences in survival, and the sample size may limit the generalizability of the findings.
Participant Demographics
Patients were aged 18 and older with stage IIIb–IV non-small-cell lung cancer who had failed first-line treatment.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI, 6–26 for D arm; 95% CI, 2–18 for DI arm
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website